Form 4: Intensity Therapeutics CFO Granted Stock Options
SEC Form 4 Filing
Joseph Talamo, CFO of Intensity Therapeutics, was granted stock options for 300,000 shares of common stock.
Summary
- Joseph Talamo, the Chief Financial Officer of Intensity Therapeutics, Inc., was granted stock options to purchase 300,000 shares of the company's common stock on May 2, 2025.
- The exercise price of these options is $0.57 per share.
- The options vest in five equal annual installments, starting on May 2, 2025, contingent upon continued employment with Intensity Therapeutics, Inc.
- Talamo also signed a Power of Attorney on October 29, 2024, authorizing certain individuals to execute forms related to Section 16 filings on his behalf.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.
Positives
- The granting of stock options to the CFO aligns his interests with those of the shareholders.
- The vesting schedule encourages continued employment and commitment to the company.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize and retain key executives.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen routinely grant stock options to their executives as part of their overall compensation strategy.
- The vesting schedule of five years is also typical, aligning with industry norms for long-term incentive plans.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive incentive for the CFO to drive company performance.
- Employees may see this as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 2024-10-29 | Date of Power of Attorney execution by Joseph Talamo. |
| 2025-05-02 | Date of stock option grant and start of vesting period. |
| 2025-05-06 | Date of Form 4 filing. |
| 2035-05-02 | Expiration date of the stock options. |
Keywords
stock options, Intensity Therapeutics, Form 4, Joseph Talamo, CFO, Section 16, beneficial ownership, power of attorney
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.